{"id":"W2597637166","doi":"10.1200/jco.2012.30.15_suppl.e13011","title":"Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: A phase I dose escalation trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada); Juravinski Cancer Centre; University of Alberta","funders":"","keywords":"Medicine; Afatinib; Erlotinib; Internal medicine; Cohort; Maximum tolerated dose; Toxicity; Gastroenterology; Cancer; Oncology; Surgery; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00106729,0.001303517,0.001520247,0.0004078438,0.0003654949,0.0007959817,0.0006746434,0.001039373,0.002603926],"category_scores_gemma":[0.0005986021,0.0005506114,0.000915924,0.0005335644,0.0008932558,0.0007919057,0.0003912995,0.002599877,0.0007329097],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007618121,"about_ca_system_score_gemma":0.001015596,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005056423,"about_ca_topic_score_gemma":0.001058527,"domain_scores_codex":[0.9997706,0.00009776797,0.00001547783,0.00004921068,0.00002299025,0.00004393055],"domain_scores_gemma":[0.999556,0.00007301589,0.00009094101,0.00003220904,0.00001950892,0.0002283152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6927585,0.09220342,0.01022528,0.001340592,0.001353185,0.0006726984,0.000597768,0.006778077,0.05379884,0.0004402938,0.005362327,0.134469],"study_design_scores_gemma":[0.5809405,0.3996534,0.01080378,0.00003740784,0.000346121,0.0005657648,0.00006511109,0.001951397,0.002945858,0.000272007,0.002389347,0.00002928884],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956751,0.00106432,0.00028701,0.0002789996,0.00004715586,0.001255338,0.0004203991,0.00005066154,0.0009209081],"genre_scores_gemma":[0.9939141,0.001092239,0.001029225,0.0004447617,0.00008721412,0.001426663,0.0007662656,0.00001504914,0.001224513],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002603926,"threshold_uncertainty_score":0.00871098,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07679519443808776,"score_gpt":0.5008483345529107,"score_spread":0.4240531401148229,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}